Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The companies aim to expand treatment options for millions living with metabolic disorders
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Subscribe To Our Newsletter & Stay Updated